In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology … firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an …

, such as intellectual human capital, can predict where and when biotechnology enterprises emerge and agglomerate. Density … more conjectural than empirically tenable. We argue and demonstrate for biotechnology that an alternative model based on … essentially uncorrelated with the panel data on biotechnology entry by year and region while the combined model has correlation …

.S. biotechnology enterprises during 1976-1989. Using a linked cross-section/time- series panel data set, we find that the timing and … structures. We believe biotechnology may be prototypical of the birth patterns in other innovative industries …

. Here we explore the importance within the biotechnology industry of the non-financial metrics firms used to convey value … was a change over time in the importance of various metrics in determining the value of a biotechnology firm. We find that … value. Our results also suggest that the biotechnology regime changed and the Nobel Prize lost its luster as a signal of …

The biotechnology industry has been an engine of innovation for the U.S. healthcare system and, more generally, the U … American Industry Classification System (NAICS) as biotechnology firms to estimate several Fama-French three factor return … current study we find that biotechnology firms are exposed to greater financial risk than other industries and are also more …

statistical exercise is complemented by in-depth interviews with six pharmaceutical and biotechnology firms. The qualitative …

biotechnology firms, I explain why outsourcing deals take the form of embedded relationships in the first setting, and of seemingly …